Evidence map›Paper›PMID 40079203›Full record

ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025

Controversy and multiple roles of the solitary nucleus receptor Nur77 in disease and physiology.

Yanteng Wang, Na Li, Wenwei Guan, Difei Wang

Abstract readReview
In one paragraph

Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Controversy and multiple roles of the solitary nucleus receptor Nur77 in disease and physiology.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yanteng WangDepartment of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.ORCID https://orcid.org/0000-0001-6807-2041
Na LiDepartment of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.ORCID https://orcid.org/0009-0003-9650-4755
Wenwei GuanDepartment of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.ORCID https://orcid.org/0009-0004-0306-4103
Difei WangDepartment of Gerontology and Geriatrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.ORCID https://orcid.org/0000-0002-1118-658X

Funding

Department of Science and Technology of Liaoning Province 2023-BSBA-334MOST | National Natural Science Foundation of China (NSFC) 92249305
6 · The paper itself

Abstract

Neuron-derived clone 77 (Nur77), a member of the orphan nuclear receptor family, is expressed and activated rapidly in response to diverse physiological and pathological stimuli. It exerts complex biological functions, including roles in the nervous system, genome integrity, cell differentiation, homeostasis, oxidative stress, autophagy, aging, and infection. Recent studies suggest that Nur77 agonists alleviate symptoms of neurodegenerative diseases, highlighting its potential as a therapeutic target in such conditions. In cancer, Nur77 demonstrates dual roles, acting as both a tumor suppressor and promoter, depending on the cancer type and stage, making it a controversial yet promising anticancer target. This review provides a structured analysis of the functions of Nur77, focusing on its physiological and pathological roles, therapeutic potential, and existing controversies. Emphasis is placed on its emerging applications in neurodegenerative diseases and cancer, offering key insights for future research and clinical translation.

Indexed as

NeoplasmsNeurodegenerative DiseasesNuclear Receptor Subfamily 4, Group A, Member 1AnimalsAutophagyHumansOxidative StressNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1cancerneurodegenerationNur77physiological functiontranscription

Identifiers

PMID40079203
PMCPMC11904867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.